9 April 2022

PBAC Recommendation for nirmatrelvir and ritonavir (Paxlovid®) March 2022

The Pharmaceutical Benefits Advisory Committee (PBAC) undertook an expedited consideration of a submission to add the combination product, nirmatrelvir and rito...

Read More